Related Experiment Video

Updated: Jul 6, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

[Adenovirus mediated targeted genetherapy of Staphylococcal enterotoxin A and CD80 for hepatoma and its primary

Shao-yan Si1, Pei-zhen Hu, Yang Huang

  • 1Experimental Center for Medicine, 306th Hospital of PLA, Beijing 100101, China. sishy306@yahoo.com.cn

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology
|March 11, 2008
PubMed
Abstract

Insights

Hepatoma-targeting recombinant adenovirus vectors carrying staphylococcal enterotoxin A (SEA) and CD80 genes show significant antitumor effects. Dual-gene therapy demonstrated superior efficacy compared to single-gene treatments, enhancing immune responses and improving survival in hepatoma models.

Area of Science:

  • Oncolytic virology
  • Immunotherapy
  • Gene therapy

Background:

  • Hepatocellular carcinoma (HCC) remains a significant global health challenge.
  • Developing targeted therapies with enhanced immunogenicity is crucial for improving HCC treatment outcomes.
  • Recombinant adenovirus vectors offer a promising platform for delivering therapeutic genes to tumor cells.

Purpose of the Study:

  • To construct and evaluate hepatoma-targeting recombinant adenovirus vectors expressing staphylococcal enterotoxin A (SEA) and/or CD80.
  • To investigate the immunological mechanisms underlying the antitumor effects of these vectors.
  • To assess the therapeutic efficacy of single-gene (SEA or CD80) versus dual-gene (SEA and CD80) therapy in a hepatoma model.

Main Methods:

  • Construction of recombinant adenovirus vectors using the AdEasy system, driven by the alpha-fetoprotein (AFP) enhancer I and promoter.
  • Intratumoral administration of vectors in mice bearing subcutaneous xenograft hepatoma.
  • Detection of gene and protein expression (SEA, CD80) via RT-PCR and Western blot.
  • Assessment of immune responses, including IFN-gamma-producing T cells (ELISpot) and cytotoxic T lymphocyte activity (LDH assay).
  • Evaluation of antitumor effects by measuring tumor volume and survival time.

Main Results:

  • Targeted expression of SEA and/or CD80 mRNA and protein in hepatoma tissues was confirmed.
  • Recombinant adenovirus treatment led to increased IFN-gamma-producing T cells and specific T lymphocyte cytotoxicity.
  • Significant reduction in tumor volumes and prolonged survival were observed in both single-gene and dual-gene therapy groups.
  • Dual-gene therapy (SEA and CD80) exhibited superior antitumor effects and stronger immune responses compared to single-gene therapies.
  • No significant differences were noted between the CD80 and SEA single-gene groups, or between the empty vector and PBS control groups.

Conclusions:

  • Hepatoma-targeting recombinant adenovirus vectors expressing SEA and/or CD80 are effective in eliciting antitumor responses.
  • Dual-gene therapy with SEA and CD80 demonstrates enhanced efficacy over single-gene therapy for hepatoma.
  • These findings support the potential of combination gene therapy using oncolytic adenoviruses for HCC treatment.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...